Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $38.75 USD
Change Today +0.63 / 1.65%
Volume 1.0M
ACAD On Other Exchanges
As of 8:10 PM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

acadia pharmaceuticals inc (ACAD) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/10/15 - $46.48
52 Week Low
05/7/14 - $17.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

acadia pharmaceuticals inc (ACAD) Related Businessweek News

No Related Businessweek News Found

acadia pharmaceuticals inc (ACAD) Details

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead product candidate is NUPLAZID, which completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis; is in Phase II study for Alzheimer’s disease psychosis; and has completed Phase II trial for the treatment of schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

97 Employees
Last Reported Date: 02/26/15
Founded in 1993

acadia pharmaceuticals inc (ACAD) Top Compensated Officers

Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $605.0K
General Counsel, Corporate Compliance Officer...
Total Annual Compensation: $445.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $178.1K
Compensation as of Fiscal Year 2013.

acadia pharmaceuticals inc (ACAD) Key Developments

ACADIA Pharmaceuticals Inc. Appoints Ernst & Young LLP as Independent Registered Public Accounting Firm

The audit committee of the board of directors of ACADIA Pharmaceuticals Inc. on March 27, 2015, approved the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2015, including the fiscal quarter ending March 31, 2015.

ACADIA Pharmaceuticals Inc. Appoints Daniel Soland to Board of Directors

ACADIA Pharmaceuticals Inc. announced that Daniel Soland has joined its Board of Directors. Mr. Soland is a seasoned pharmaceutical executive with over 30 years of experience in the biopharmaceutical industry. In addition to his extensive commercial experience in launching new drugs and life cycle management, he has led manufacturing and quality organizations and has been instrumental in driving growth in the companies he has served. Mr. Soland previously served as Senior Vice President and Chief Operating Officer of ViroPharma starting in 2008 until it was acquired in 2014, and as Vice President and Chief Commercial Officer of the Company from 2006 to 2008.

ACADIA Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 09:20 AM

ACADIA Pharmaceuticals Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 09:20 AM. Venue: Westin Grand Central Hotel, New York, New York, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACAD:US $38.75 USD +0.63

ACAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acorda Therapeutics Inc $34.67 USD -0.22
Depomed Inc $26.49 USD -0.23
Impax Laboratories Inc $49.98 USD +0.12
Isis Pharmaceuticals Inc $66.29 USD +1.13
View Industry Companies

Industry Analysis


Industry Average

Valuation ACAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31,719.0x
Price/Book 12.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 29,133.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACADIA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at